Saturday 17 October 2026
Export FBIO’s income statement to Excel — free account
Fortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024. In the quarter to June 2026, revenue grew 14.0%, EPS fell 116.0%, free cash flow fell 115.4% and total debt fell 35.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.87
0.04
−2.09%
Follow FBIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.73 | 0.94 |
P/S ratio |
1.62 | 1.61 | 1.33 | 1.42 | |
P/FCF ratio |
0.00 | 0.00 | 0.74 | 1.13 | |
P/Operating CF |
(16.50) | (8.14) | 0.43 | (1.64) | |
P/B ratio |
1.55 | 1.64 | 0.43 | 0.47 | |
Price to Tangible BV |
2.76 | 2.95 | 0.50 | 0.54 | |
EV/Sales |
1.06 | 1.25 | (1.92) | (0.89) | |
EV/EBITDA |
0.00 | 0.00 | 2.74 | 3.00 | |
EV/Operating CF |
(1.00) | (1.20) | (0.81) | (0.48) | |
EV/FCF |
(0.63) | (0.75) | (1.07) | (0.71) | |
Quick Ratio |
1.93 | 2.20 | 2.72 | 3.76 | |
Current Ratio |
2.19 | 2.49 | 2.86 | 3.96 | |
Net Debt/EBITDA |
7.94 | 10.18 | 47.76 | 19.62 | |
Debt/Assets |
26.34% | 28.25% | 10.33% | 10.93% | |
Debt/Equity |
0.73 | 0.84 | 0.18 | 0.17 | |
Asset Turnover |
0.40 | 0.38 | 0.25 | 0.29 | |
Operating CF/Net income |
(1.66) | 2.02 | 1.88 | 23.94 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.05) | |
Interest Coverage |
(2.48) | (2.26) | (2.30) | (6.78) | |
Research and Development Expense of Revenue |
1.18% | (2.31%) | 3.37% | 4.30% | |
Selling, General and Administrative Expense of Revenue |
98.77% | 90.58% | 99.10% | 111.16% | |
Intangible Assets out of Total Assets |
0.16 | 0.15 | 0.07 | 0.08 | |
Share Based Compensation of Revenue |
18.14% | 15.29% | 10.48% | 15.78% | |
Graham Net Nets |
0.02 | 0.00 | 1.60 | 1.39 | |
Graham Number |
0.00 | 0.00 | 23.54 | 21.81 | |
Earnings Yield |
(12.45%) | (2.19%) | 137.63% | 106.54% | |
Free Cash Flow Yield |
(104.20%) | (102.44%) | 135.00% | 88.24% | |
Revenue per Share |
0.65 | 0.58 | 0.51 | 0.59 | |
Operating CF per Share |
(0.22) | (0.45) | 6.46 | (1.86) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.45) | 6.46 | (1.87) | |
Cash per Share |
3.16 | 2.85 | 8.11 | 6.18 | |
Shareholders Equity per Share |
2.39 | 2.23 | 6.42 | 6.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.39 | 2.23 | 6.42 | 6.48 | |
Free Cash Flow |
(6.11) | (12.54) | 203.85 | (59.36) | |
Working Capital |
64.44 | 74.10 | 192.09 | 183.49 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.08) | |
Net Current Asset Value |
2.28 | 0.48 | 140.98 | 134.88 | |
EV/EBIT |
0.00 | 0.00 | 2.29 | 2.09 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.49 | 20.17 | 21.92 | 26.48 | |
Average Payables |
54.84 | 56.31 | 79.64 | 48.95 | |
Average Inventory |
11.80 | 12.03 | 10.89 | 10.50 | |
Average Assets |
154.25 | 164.89 | 267.47 | 238.31 | |
Average Common Equity |
26.22 | 30.27 | 117.43 | 121.73 |
Columns are period end dates